News & Updates

Show Multimedia Only

Response to nucleos(t)ide analogues for hepatitis B higher among men vs women

25 Sep 2023

Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.

Response to nucleos(t)ide analogues for hepatitis B higher among men vs women

25 Sep 2023

Dupilumab beneficial in treatment of bullous pemphigoid

24 Sep 2023

Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.

Dupilumab beneficial in treatment of bullous pemphigoid

24 Sep 2023

Anticoagulation during CKRT reduces dialysis, death in AKI patients

24 Sep 2023 by

Use of anticoagulants during continuous kidney replacement therapy (CKRT) helps lower dialysis dependence and prevent death at 90 days among critically ill patients with acute kidney injury (AKI) following admission to the intensive care unit (ICU), a study in Singapore has shown.

Anticoagulation during CKRT reduces dialysis, death in AKI patients

24 Sep 2023

Several factors must be considered when tapering adalimumab in noninfectious uveitis patients

24 Sep 2023

For patients who undergo adalimumab tapering after achieving remission, factors such as age, race, and duration of disease remission on adalimumab appear to impact the risk of relapse, according to a study.

Several factors must be considered when tapering adalimumab in noninfectious uveitis patients

24 Sep 2023

Tirzepatide a valuable therapeutic option for weight management

23 Sep 2023

Treatment with tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes, leads to substantial reductions in weight despite an increase in gastrointestinal symptoms, according to the results of a meta-analysis.

Tirzepatide a valuable therapeutic option for weight management

23 Sep 2023

$3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG$

3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG

23 Sep 2023

In the treatment of patients with 3-vessel coronary artery disease (CAD), fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) does not differ from coronary artery bypass grafting (CABG) in terms of the incidence of the composite of death, myocardial infarction (MI), or stroke, according to 3-year data from the FAME 3* trial.

3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG

23 Sep 2023

Benralizumab helps maintain severe asthma control with reduced ICS doses

22 Sep 2023 by

Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.

Benralizumab helps maintain severe asthma control with reduced ICS doses

22 Sep 2023

Antidepressant use among HCC patients linked to lower risk of death

22 Sep 2023

For patients with hepatocellular carcinoma (HCC), the use of antidepressants after diagnosis may signal increased overall and cancer-specific survival, according to a study.

Antidepressant use among HCC patients linked to lower risk of death

22 Sep 2023

Benralizumab reduces asthma exacerbations in Asians

22 Sep 2023 by

Treatment with benralizumab significantly reduces the annual asthma exacerbation rate (AAER) among Asian patients with severe uncontrolled asthma compared with placebo, according to a subgroup analysis of the MIRACLE trial presented at ERS 2023.

Benralizumab reduces asthma exacerbations in Asians

22 Sep 2023

Chlorpheniramine nasal spray alleviates long COVID symptoms

21 Sep 2023 by

Inhaled chlorpheniramine maleate appears to reduce the risk of prolonged post-COVID symptoms, according to a study presented at ERS Congress 2023.

Chlorpheniramine nasal spray alleviates long COVID symptoms

21 Sep 2023

News & Updates

Filter by Specialty:

Specialty:

Response to nucleos(t)ide analogues for hepatitis B higher among men vs women

Response to nucleos(t)ide analogues for hepatitis B higher among men vs women

Dupilumab beneficial in treatment of bullous pemphigoid

Dupilumab beneficial in treatment of bullous pemphigoid

Anticoagulation during CKRT reduces dialysis, death in AKI patients

Anticoagulation during CKRT reduces dialysis, death in AKI patients

Several factors must be considered when tapering adalimumab in noninfectious uveitis patients

Several factors must be considered when tapering adalimumab in noninfectious uveitis patients

Tirzepatide a valuable therapeutic option for weight management

Tirzepatide a valuable therapeutic option for weight management

3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG

3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG

Benralizumab helps maintain severe asthma control with reduced ICS doses

Benralizumab helps maintain severe asthma control with reduced ICS doses

Antidepressant use among HCC patients linked to lower risk of death

Antidepressant use among HCC patients linked to lower risk of death

Benralizumab reduces asthma exacerbations in Asians

Benralizumab reduces asthma exacerbations in Asians

Chlorpheniramine nasal spray alleviates long COVID symptoms

Chlorpheniramine nasal spray alleviates long COVID symptoms